Roivant Sciences vs Viridian Therapeutics, Inc.\DE
ROIV and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ROIV and VRDN compare
Roivant Sciences is the larger company, worth 8.2 times as much as Viridian Therapeutics, Inc.\DE ($28.0B against $3.4B).
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −67.6% for Roivant Sciences).
Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −3535% at Roivant Sciences.
Roivant Sciences scores higher on the StockData Score (7 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ROIV | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | $28.0B | $3.4B |
| Share price | $38.71 | $30.06 |
| Change, 1 year | 90.8% | 4.5% |
| Change, 5 years | 453% | 64.3% |
| Beta (5Y) | 0.42 | −0.13 |
| Employees | 721 | 252 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3712× | 47.9× (better) |
| P/B | 6.6× | 5.1× (better) |
| FCF yield | −2.9% (better) | −9.8% |
| Fair value | – | $8.47 |
| Margin of safety | – | −255% |
| Growth | ||
| Revenue growth (TTM) | −67.6% | 23220% (better) |
| Revenue growth, 5Y average | −19.1% | 132% (better) |
| Profitability | ||
| Operating margin | −7915% | −570% (better) |
| Net margin | −3535% | −544% (better) |
| FCF margin | −10901% | −471% (better) |
| Return on equity | −6.2% (better) | −65.7% |
| Return on invested capital | −407% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −26.0× |
| Current ratio | 16.72 | 16.95 (better) |
| Altman Z-score | 44.02 (better) | 2.65 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −1.7% |
| Shareholder yield | 0.00% (better) | −1.7% |
| Ownership | ||
| Held by institutions | 78.1% | 120% |
| Held by insiders | 13.9% | 21.8% |
| Insider net buying, 12 months | −$798M | $19.6M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.3% | 19.2% |
Go deeper
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.